Health expenditure per capita for the rheumatoid arthritis (RA) and control group.

For interpretation, 1 US dollar is equal to 1100 Korean dollars. (A) Total health care costs. (B) Amount of out-of-pocket payment.</p

Flowchart of the selection of study participants.

*Methotrexate, sulfasalazine, hydroxychloroquine, leflunomide, tacrolimus, bucillamine, mizoribine, cyclosporine, infliximab, etanercept, adalimumab, golimumab, abatacept, tocilizumab, rituximab, and tofacitinib. **Systemic connective tissue disorders (International Classification of Diseases 10th revision [ICD-10] code: M30-M36), ankylosing spondylitis (ICD-10 code: M45), psoriatic and enteropathic arthropathies (ICD-10 code: M07), or juvenile arthritis (ICD-10 code: M08). RA, rheumatoid arthritis; DMARD, disease-modifying anti-rheumatic drug.</p

Comparison of mortality between the RA and control groups.

Comparison of mortality between the RA and control groups.</p

Comparison of rate, type, and distribution of disability between the RA and control groups.

Comparison of rate, type, and distribution of disability between the RA and control groups.</p

Sociodemographic characteristics of the RA and control groups.

Sociodemographic characteristics of the RA and control groups.</p